ATE557041T1 - Peptid-vakzinen gegen streptokokken der gruppe a - Google Patents

Peptid-vakzinen gegen streptokokken der gruppe a

Info

Publication number
ATE557041T1
ATE557041T1 AT02734477T AT02734477T ATE557041T1 AT E557041 T1 ATE557041 T1 AT E557041T1 AT 02734477 T AT02734477 T AT 02734477T AT 02734477 T AT02734477 T AT 02734477T AT E557041 T1 ATE557041 T1 AT E557041T1
Authority
AT
Austria
Prior art keywords
peptides
antibodies
compositions
vaccines
relates
Prior art date
Application number
AT02734477T
Other languages
English (en)
Inventor
Bernard Beall
George Carlone
Jacquelyn Sampson
Edwin Ades
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE557041T1 publication Critical patent/ATE557041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02734477T 2001-05-18 2002-05-20 Peptid-vakzinen gegen streptokokken der gruppe a ATE557041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29183501P 2001-05-18 2001-05-18
PCT/US2002/015909 WO2002094851A2 (en) 2001-05-18 2002-05-20 Peptide vaccines against group a streptococci

Publications (1)

Publication Number Publication Date
ATE557041T1 true ATE557041T1 (de) 2012-05-15

Family

ID=23122046

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734477T ATE557041T1 (de) 2001-05-18 2002-05-20 Peptid-vakzinen gegen streptokokken der gruppe a

Country Status (5)

Country Link
US (5) US7407664B2 (de)
EP (1) EP1399181B1 (de)
AT (1) ATE557041T1 (de)
CA (2) CA2881980A1 (de)
WO (1) WO2002094851A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
CA2881980A1 (en) * 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US20090317420A1 (en) * 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
EP2173902A4 (de) * 2007-07-03 2013-01-09 Mt Sinai Hospital Therapeutika und diagnostika für gruppe-a-streptokokken
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
AU2014214613A1 (en) 2013-02-11 2015-08-13 University Of Tennessee Research Foundation Group A streptococcal M-related proteins and methods of use
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
AU2019268417A1 (en) * 2018-05-16 2020-12-03 Griffith University Streptococcal toxic shock syndrome
EP4240843A1 (de) 2020-11-04 2023-09-13 Eligo Bioscience Rekombinante phagen von cutibacterium acnes, herstellungsverfahren und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
CA2123580C (en) 1992-09-16 2005-04-26 James B. Dale Antigen of hybrid m protein and carrier for group a streptococcal vaccine
WO1994006421A1 (en) 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
EP1003875B1 (de) * 1997-09-12 2006-12-27 University of Tennessee Research Foundation Gruppe a streptokokken-impfstoff
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
CA2881980A1 (en) * 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci

Also Published As

Publication number Publication date
CA2447599A1 (en) 2002-11-28
US20050220808A1 (en) 2005-10-06
EP1399181B1 (de) 2012-05-09
WO2002094851A3 (en) 2003-10-30
EP1399181A4 (de) 2006-06-28
US20110110969A1 (en) 2011-05-12
US20120177685A1 (en) 2012-07-12
CA2881980A1 (en) 2002-11-28
WO2002094851A2 (en) 2002-11-28
US20080279880A1 (en) 2008-11-13
US7407664B2 (en) 2008-08-05
US8420107B2 (en) 2013-04-16
US7883710B2 (en) 2011-02-08
CA2447599C (en) 2015-04-28
US20130202635A1 (en) 2013-08-08
EP1399181A2 (de) 2004-03-24
US8637050B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
IS6722A (is) Samsetning bóluefnis
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2001079274A3 (en) Tuberculosis antigens and methods of use thereof
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2009074318A3 (en) Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ATE356140T1 (de) Gd3 mimetische peptide
DE60234475D1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2003038061A3 (en) Ehrlichia disulfide bond formation proteins and uses thereof
ATE338126T1 (de) Dna-sequenz und rekombinante herstellung eines graminaen-allergens
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen